Abstract

Chronic Kidney Disease [CKD] is one of the most burdensome disease with high mortality rate globally. Even though there are diagnostically accepted markers for the detection of CKD, the unreliability of the non-specific marker is a lacuna in the clinical world for an early prognosis and prevention of this chronic disease. Further, the economically challenging conventional treatment options available currently are a burden for many low-income countries to overcome this disease. This article discusses the current treatment scenario for CKD, and limitations of the diagnostic and treatment options available for CKD.

Keywords: Chronic Kidney Disease; Indian CKD Burden; Diagnostic Tools; Prognosis; Treatment and Limitations; Novel Biomarkers

References

1. Vos T., et al. “Global, regional, and national incidence, prevalence, and years lived with disability for 301acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013”. Lancet 9995 (2015): 743-800.
2. Naghavi M., et al. “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013”. Lancet (2015).
3. Ene-Iordache B., et al. “Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): Across-sectional study”. The Lancet Global Health (2016).
4. Levin A., et al. “Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO2012 clinical practice guideline for the evaluation and management of chronic kidney disease”. Kidney International Supplements (2013).
5. Bharati J., et al. “The Global Kidney Health Atlas: Burden and Opportunities to Improve Kidney Health Worldwide”. Annals of Nutrition and Metabolism (2021).
6. Carney EF. “The impact of chronic kidney disease on global health”. Nature Reviews Nephrology (2020).
7. Chapter 3: Morbidity and Mortality in Patients with CKD”. The American Journal of Kidney Diseases (2019).
8. Davies R. “The metabolomic quest for a biomarker in chronic kidney disease”. Clinical Kidney Journal (2018).
9. Johnson CA., et al. “Clinical practice guidelines for chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers”. American Family Physician (2004).
10. Delanaye P., et al. “Serum Creatinine: Not so Simple! Nephron (2017).
11. Waikar SS and Bonventre J V. “Creatinine kinetics and the definition of acute kidney injury”. Journal of the American Society of Nephrology (2009).
12. Lopez-Giacoman S. “Biomarkers in chronic kidney disease, from kidney function to kidney damage”. World Journal of Nephrology (2015).
13. Nordin F., et al. “Serum and urine interleukin-17A levels as biomarkers of disease activity insystemic lupus erythematosus”. International Journal of Rheumatic Diseases (2019).
14. Curhan G. “Cystatin C: A marker of renal function or something more?” Clinical Chemistry (2005).
15. Benoit SW., et al. “Cystatin C as a biomarker of chronic kidney disease: latest developments”. Expert Review of Molecular Diagnostics (2020).
16. Tonelli M and Dickinson JA. “Early Detection of CKD: Implications for Low-Income, Middle-Income, and High-Income Countries”. Journal of the American Society of Nephrology (2020).
17. Liu KZ., et al. “Detection of renal biomarkers in chronic kidney disease using microfluidics: progress, challenges and opportunities”. Biomed Microdevices (2020).
18. Bello AK., et al. “Prevention of chronic kidney disease: A global challenge”. Kidney International Supplements (2005).
19. Delanaye P and Rule AD. “Assessing Kidney Function”. In: Chronic Renal Disease (2015).
20. Lai S., et al. “Prebiotic therapy with inulin associated with low protein diet in chronic kidney disease patients: Evaluation of nutritional, cardiovascular and psychocognitive parameters”. Toxins (2020).
21. Argyropoulos CP., et al. “Rediscovering Beta-2 microglobulin as a biomarker across the spectrum of kidney diseases”. Frontiers in Medicine (2017).
22. Scarr D., et al. “Estimating GFR by Serum Creatinine, Cystatin C, and β2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes”. Kidney Int Reports (2019).
23. Shah B V and Patel ZM. “Role of low protein diet in management of different stages of chronic kidney disease - Practical aspects”. BMC Nephrology (2016).
24. Wang M., et al. “The role of low protein diet in ameliorating proteinuria and deferring dialysis initiation: What is old and what is new”. Panminerva Medica (2017).
25. Wasung ME., et al. “Biomarkers of renal function, which and when?” Clinica Chimica Acta (2015).
26. Kumar V., et al. “Existing creatinine-based equations overestimate glomerular filtration rate in Indians”. BMC Nephrology (2018).
27. Kurniawan AL., et al. “Association of kidney function-related dietary pattern, weight status, and cardiovascular risk factors with severity of impaired kidney function in middle-aged and older adults with chronic kidney disease: a cross-sectional population study”. Nutrition Journal (2019).
28. Metzger M., et al. “Association of a Low-Protein Diet With Slower Progression of CKD”. Kidney International Reports (2018).
29. Maxia S., et al. “Compliance, illiteracy and low-protein diet: Multiple challenges in CKD and a case of self-empowerment”. BMC Nephrology (2016).
30. Garneata L., et al. “Ketoanalogue-supplemented vegetarian very low–protein diet and CKD progression”. Journal of the American Society of Nephrology (2016).
31. Klarenbach SW., et al. “Economic evaluation of dialysis therapies”. Nature Reviews Nephrology (2014).
32. Klarenbach S and Manns B. “Economic Evaluation of Dialysis Therapies”. Seminars in Nephrology (2009).
33. Axelrod DA. “Economic and financial outcomes in transplantation: Whose dime is it anyway?” Current Opinion in Organ Transplantation (2013).
34. Illés A., et al. “Patient Attitudes Toward Transplantation as Preferred Treatment Modality in Different Stages of Renal Disease”. Transplantation Proceedings (2017).
35. Lazarus JM. “Complications in hemodialysis: An overview”. Kidney International (1980).
36. Terrill B. “Acute complications of haemodialysis”. In: Renal Nursing (2020).
37. Kiberd BA and Tennankore KK. “Lifetime risks of kidney donation: A medical decision analysis”. BMJ Open (2017).
38. Gozdowska J., et al. “Living-Donor Versus Deceased-Donor Kidney Transplantation: Comparison ofPsychosocial Consequences for Recipients”. Transplantation Proceedings (2016).
39. Clemens K., et al. “The long-term quality of life of living kidney donors: A multicenter cohort study”. American Journal of Transplantation (2011).
40. Lam NN and Garg AX. “Acceptability of older adults as living kidney donors”. Current Opinion in Nephrology and Hypertension (2016).

Citation

Citation: Bhavya Vijay. “Chronic Kidney Disease: Current Scenario of Diagnosis and Treatment in India”. Acta Scientific Gastrointestinal Disorders 4.11 (2021): 12-15.

Copyright

Copyright: © 2021 Bhavya Vijay. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.